Overview
-
- Name
- Chiome Bioscience Inc.
-
- Business
- Chiome Bioscience (4583.T), is a public company leveraging the ADLib® System, a proprietary monoclonal antibody generating technology, for drug discocery and development, as well as providing drug discovery supports.
-
- Address
-
[ Headquarters, Research Laboratories]
Sumitomo-Fudosan Nishi-shinjuku bldg. No.6, 3-12-1
Honmachi, Shibuya-ku, Tokyo 151-0071 Japan[Drug Discovery Laboratories]
Teikyo University Biotechnology Research Center 1F
2-13-3 Nogawahonmachi, Miyamae-ku, Kawasaki-city, Kanagawa 216-0041 Japan
-
- Date of Establishment
- February 8, 2005
-
- Capital
- 1,554 million yen （As of Jun 30,2026）
-
- Number of Employees
- 63（As of Jun 30,2026）
-
- Banks of Account
- Sumitomo Mitsui Banking Corporation, Mizuho Bank, Ltd.
History
-
- 2005.02
- Chiome Bioscience Inc. (capital: 10 million yen) was established in the Bunkyo district of Tokyo to commercialize the ADLib® system developed through the collaboration of the Genetic Dynamics Research Unit at RIKEN, headed by Dr. Kunihiro Ohta (currently serving as a Technical Advisor at Chiome Bioscience Inc.), and the Saitama Small and Medium Enterprise Development Corporation (currently Saitama Industrial Development Corporation).
-
- 2005.04
- Chiome Bioscience Inc. concluded an agreement with RIKEN to commercialize the ADLib® system, and research activities begins.
-
- 2005.07
- CHIOME has obtained an exclusive license to commercialize platform technology (the ADLib® System) from RIKEN Institute and the Japanese Science and Technology Agency. And CHIOME can sublicense this technology to other third parties.
-
- 2009.10
- The head office has relocated to Shinjuku ward, Tokyo.
-
- 2010.08
- Chiome Bioscience Inc. concluded a payment based technology transfer agreement with the Japan Science and Technology Agency on the platform technology - the ADLib® System.
-
- 2011.12
- CHIOME is now listed on Tokyo Stock Exchange Mothers Index.
-
- 2013.05
- The head office has relocated to Shibuya ward, Tokyo.
-
- 2013.12
- Chiome Bioscience Inc. acquired a majority of Liv Tech, Inc.'s capital.
-
- 2015.07
- Chiome Bioscience Inc. merged with Liv Tech, Inc.
-
- 2015.10
- Chiome Bioscience Inc. executed an investment in capital of to EVEC, Inc.
-
- 2017.02
- Chiome Bioscience Inc. acquired new shares of Trans Chromosomics, Inc. issued in a third- party allotment.
-
- 2017.09
- Chiome Bioscience Inc. executed a License Agreement with ADC Therapeutics SA for the development, manufacture, and commercialization of an ADC of LIV-1205.
-
- 2018.12
- Chiome Bioscience Inc. executed an Asset Purchase Agreement of Tb535H（currently CBA-1535） and Trisoma® technology with Biotecnol Limited
-
- 2020.07
- Phase I clinical trial of CBA-1205, an antibody for cancer treatment, started as Chiome Bioscience's first clinical study.
-
- 2021.01
- Chiome Bioscience Inc. executed a License Agreement with Shanghai Henlius Biotech, Inc. for the development and commercialization of the anti-TROP-2 antibodies, LIV-2008/2008b.This License Agreement ended in January 2023.
-
- 2022.04
- Shift from the Tokyo Stock Exchange Mothers Index to the Growth Index due to the reorganization of the market segment of the Tokyo Stock Exchange.
-
- 2022.06
- Phase I clinical trial of CBA-1535, a multi-specific antibody for cancer treatment, started as the world's first clinical trial of Tribody™.
-
- Current
More
OriginMeaning of the Company Name
“Chiome” (pronounced as “kai-ohm”) is a fusion word from “Chiasma” and “-ome.” The “chi” (pronounced as “kai”) of Chiome is the “chi” of “Chiasma.” “Chiasma” is the point of contact between paired chromatids during meiosis, resulting in a cross-shaped configuration. It is the cytological manifestation of crossing over, representing the blending of genes and the birth of a new generation. The “-ome” of Chiome is the same as the “-ome” of “Genome” and “-ome” of “Proteome,” which carries the meaning of “collectivity.” The name Chiome therefore signifies “Exchange,” “Diversity,” “Sustainable” and “Fusion.”